Phase I study of hepatic arterial infusion of floxuridine and dexamethasone with systemic irinotecan for unresectable hepatic metastases from colorectal cancer.

PURPOSE To determine the maximum-tolerated dose (MTD) and dose-limiting toxicities of concurrent systemic irinotecan and hepatic arterial infusion (HAI) of floxuridine (FUDR) and dexamethasone in patients with unresectable hepatic metastases from colorectal cancer, to determine the safety of this combination in patients who have undergone cryosurgery, and to evaluate the pharmacokinetic effects of HAI FUDR on the metabolism of irinotecan. PATIENTS AND METHODS Forty-six previously treated patients with unresectable liver metastases and no known extrahepatic disease were treated concurrently with intravenous irinotecan weekly for 3 weeks and with HAI of FUDR and dexamethasone for 14 days (both were recycled in 28 days). Parallel cohorts of patients treated with or without cryosurgery were entered at escalating dose levels. RESULTS The MTD for patients who did not undergo cryosurgery was 100 mg/m2 of irinotecan weekly for 3 weeks every 4 weeks with concurrent HAI FUDR (0.16 mg/kg/d x pump volume/flow rate) plus dexamethasone for 14 days of a 28-day cycle. The dose-limiting toxicities were diarrhea and neutropenia. The response rate (complete and partial) among all patients who did not undergo cryosurgery was 74%. All patients in the cryosurgery group responded, and seven of the eight cryosurgery patients developed normal positron emission tomography scans after chemotherapy. HAI FUDR had no effect on the metabolism of irinotecan. CONCLUSION Combination therapy with HAI FUDR and dexamethasone plus systemic irinotecan may be safely administered to patients with unresectable hepatic metastases from colorectal cancer. The MTD has been reached for patients with unresectable disease, and we continue to investigate the MTD for patients who have undergone cryosurgery. Although the main objective of this study was to evaluate the toxicity of the combined regimen, a high response rate (74%) was observed.

[1]  N. Kemeny,et al.  A randomized trial of intrahepatic infusion of fluorodeoxyuridine with dexamethasone versus fluorodeoxyuridine alone in the treatment of metastatic colorectal cancer , 1992, Cancer.

[2]  W. Enker,et al.  Liver resection for colorectal metastases. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  S. Groshen,et al.  Quantitation of intratumoral thymidylate synthase expression predicts for resistance to protracted infusion of 5-fluorouracil and weekly leucovorin in disseminated colorectal cancers: preliminary report from an ongoing trial. , 1995, European journal of cancer.

[4]  N. Kemeny,et al.  Continuous intrahepatic infusion of floxuridine and leucovorin through an implantable pump for the treatment of hepatic metastases from colorectal carcinoma , 1990, Cancer.

[5]  N. Saijo,et al.  Simultaneous administration of CPT-11 and fluorouracil: alteration of the pharmacokinetics of CPT-11 and SN-38 in patients with advanced colorectal cancer. , 1994, Journal of the National Cancer Institute.

[6]  H. Bierman,et al.  Studies on the blood supply of tumors in man. III. Vascular patterns of the liver by hepatic arteriography in vivo. , 1951, Journal of the National Cancer Institute.

[7]  S. Culine,et al.  Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  L H Blumgart,et al.  Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. , 1999, The New England journal of medicine.

[9]  S. Larson,et al.  Positron emission tomography imaging of colorectal cancer. , 1999, Seminars in oncology.

[10]  P. Piedbois.  Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  S. Jhanwar,et al.  Higher levels of thymidylate synthase gene expression are observed in pulmonary as compared with hepatic metastases of colorectal adenocarcinoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  N. Kemeny,et al.  Non-surgical treatment for liver metastases. , 1999, Bailliere's best practice & research. Clinical gastroenterology.

[13]  D. V. Von Hoff,et al.  Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  F. Wilcoxon.  Individual Comparisons by Ranking Methods , 1945 .

[15]  V. Sondak,et al.  Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. , 1996, Journal of the National Cancer Institute.

[16]  W. B. Ross,et al.  Australian experience of cryoablation of liver tumors: metastases. , 1996, Surgical oncology clinics of North America.

[17]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[18]  C. Wilson,et al.  Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  N. Kemeny,et al.  Phase II study of hepatic arterial floxuridine, leucovorin, and dexamethasone for unresectable liver metastases from colorectal carcinoma. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  L. Saltz,et al.  Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. , 2000, The New England journal of medicine.

[21]  T. Ravikumar,et al.  A 5-year study of cryosurgery in the treatment of liver tumors. , 1991, Archives of surgery.

[22]  R. Labianca,et al.  Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer , 1998, The Lancet.

[23]  N. Kemeny,et al.  Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  D. Coombs,et al.  Spinal anesthesia using subcutaneously implanted pumps for intrathecal drug infusion. , 1991, Anesthesia and analgesia.